Skip to main content

Day: December 13, 2023

BioSyent Announces Renewal of Normal Course Issuer Bid

MISSISSAUGA, Ontario , Dec. 13, 2023 (GLOBE NEWSWIRE) — BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that the TSX Venture Exchange (“TSX-V”) has accepted the Company’s Notice of Intention to Make a Normal Course Issuer Bid (the “NCIB”). Pursuant to the NCIB, BioSyent may purchase up to 650,000 of its common shares (“Shares”) over a 12-month period, representing approximately 5.53% of the Shares outstanding as of December 13, 2023.   The NCIB will commence on December 19, 2023 and terminate on December 18, 2024, or such earlier date on which purchases under the NCIB have been completed. Purchases of Shares under the NCIB will be made through the facilities of the TSX-V or alternative Canadian trading systems at the market price of the Shares at the time of acquisition. The number of Shares the...

Continue reading

Nemaura Medical Inc. Receives Positive Nasdaq Listing Decision

Loughborough, UK, Dec. 13, 2023 (GLOBE NEWSWIRE) — Nemaura Medical Inc. (NASDAQ: NMRD) (“Nemaura Medical” or the “Company”), developer of a daily wear non-invasive glucose sensor, and digital healthcare programs is pleased to announce that the Nasdaq Hearings Panel granted the Company’s request for continued listing pursuant to an exception, including certain interim milestones, that ultimately expires on April 1st, 2024, to evidence compliance with all applicable criteria for continued listing on The Nasdaq Capital Market. The Company plans to continue with its commercial endeavours while pursuing its plans to ensure timely compliance with the terms of the Nasdaq Hearing Panel’s decision. About Nemaura Medical, Inc. Nemaura Medical, Inc. is a medical technology company developing and wearable diagnostic devices. The company is...

Continue reading

GK Financing LLC, a Subsidiary of American Shared Hospital Services, Announces Agreement to Reload Lovelace Medical Center with New Cobalt Sources and Software Upgrade

Installation expected to be Completed in Mid-2024 SAN FRANCISCO, Dec. 13, 2023 (GLOBE NEWSWIRE) — GK Financing LLC (GKF), a subsidiary of American Shared Hospital Services (NYSE American: AMS), and a leading provider of creative financial and turnkey technology solutions for advanced radiosurgery and radiation oncology services, announced today that it has entered into an agreement with Lovelace Medical Center (LMC), Albuquerque, NM, to reload its Gamma Knife Icon with new Cobalt Sources, as well as install Lightning Treatment Planning software that is expected to drive efficiencies, productivity and accuracy, among other benefits. GKF projects completing installation in mid-2024. Peter Gaccione, Chief Executive Officer of AMS and Board Member of GK Financing, commented, “This extension and upgrade demonstrates the confidence...

Continue reading

Acasti to Participate in Upcoming San Francisco Investor Conferences in January 2024

PRINCETON, N.J., Dec. 13, 2023 (GLOBE NEWSWIRE) — Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel intravenous formulation of nimodipine being developed to address the high unmet medical needs for a rare disease, aneurysmal Subarachnoid Hemorrhage (aSAH), today announced that Chief Executive Officer Prashant Kohli will participate in the following investor and industry networking events in San Francisco, California during the week of January 7-12, 2024. 7th Annual Sachs Neuroscience Innovation Forum – (January 7) Bio One-On-One Partnering – (January 8-9) 13th Annual LifeSci Partners Corporate Access Event – (January 10) Mr. Kohli will be presenting and available to meet with investors and potential strategic partners on the dates indicated during the three events....

Continue reading

Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) to Support DARE-PTB1 Phase 1 Human Clinical Study

DARE-PTB1 is being developed as a treatment to reduce the risk of preterm birth, for which there are no FDA-approved treatment options Up to approximately $2 million in grant funding to support DARE-PTB1 Phase 1 human clinical study SAN DIEGO, Dec. 13, 2023 (GLOBE NEWSWIRE) — Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it received a Notice of Award of a grant from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), a division of the National Institutes of Health (NIH). The award will support the clinical development of Daré’s novel, investigational intravaginal ring (IVR), DARE-PTB1. DARE-PTB1 is designed to deliver bio-identical progesterone continuously for up to a 14-day period and is being developed as a treatment for the prevention...

Continue reading

Auddia Inc. Appoints John Mahoney as Chief Financial Officer

BOULDER, CO, Dec. 13, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – Auddia Inc. (NASDAQ:AUUD) (NASDAQ:AUUDW) (“Auddia” or the “Company”), developer of a proprietary AI platform for audio and innovative technologies for podcasts that is reinventing how consumers engage with audio, today announced the appointment of John Mahoney to the role of Chief Financial Officer. Mr. Mahoney succeeds Tim Ackermann, who resigned June 30, 2023. Mr. Mahoney brings over twenty years of finance and operational experience in the services industry spanning both publicly traded and privately held companies. His Auddia appointment follows roles with Quality Biomedical, Inc., a private equity backed and leading service provider in the home medical equipment industry, where he served as CFO. While at Quality Biomedical, Mr. Mahoney...

Continue reading

Enphase Energy Expands its Support for Virtual Power Plants Across the United States

FREMONT, Calif., Dec. 13, 2023 (GLOBE NEWSWIRE) — Enphase Energy, Inc. (NASDAQ: ENPH), a global energy technology company and the world’s leading supplier of microinverter-based solar and battery systems, announced today that it is expanding its support for virtual power plants (VPPs) through grid services programs across the United States powered by the new IQ® Battery 5P. Grid services help utility companies avoid using electricity from expensive, polluting power plants when electricity demand is high. In return, homeowners can receive hundreds to thousands of dollars from the utilities towards their purchase of an Enphase® Energy System™ with IQ Battery 5P or as annual incentive payments. Most recently, homeowners who install Enphase IQ Batteries are now eligible to enroll in Pacific Gas and Electric’s (PG&E)...

Continue reading

VERB’s MARKET.live Launches National TV Campaign to Promote Its Exciting New Drop Ship Program

Highly Respected Branded Response Agency, SmartMedia Technologies Engaged To Develop and Execute Campaign Launching December 18 LOS ALAMITOS, Calif. and LAS VEGAS, Dec. 13, 2023 (GLOBE NEWSWIRE) — Verb Technology Company, Inc. (Nasdaq: VERB) (“VERB” or the “Company”), the company behind MARKET.live, the innovative multi-vendor, multi-presenter livestream social shopping platform, announces a national television campaign, launching December 18, 2023, to promote its exciting new Drop Ship Program. VERB engaged the highly regarded performance television experts, SmartMedia Technologies, to develop and execute the campaign. The MARKET.live TV commercials will air all over the country on many popular networks and television programs. Viewers can simply scan an on-screen QR code during the TV spots and be taken...

Continue reading

BioAtla Hosting Virtual R&D Day to Highlight BA3071 CAB-CTLA-4 Phase 1 Data in Multiple Solid Tumor Types

Multiple confirmed responses and durable disease control observed Emerging differentiated safety profile enables further exploration at higher doses Ongoing Phase 2 clinical study of monotherapy and in combination with a PD-1 inhibitor SAN DIEGO, Dec. 13, 2023 (GLOBE NEWSWIRE) — BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today is hosting a virtual R&D Day on its novel conditionally and reversibly active antibody targeting CTLA-4, BA3071. BA3071 is in Phase 2 development as a potential therapeutic for multiple solid tumor indications known to be responsive to CTLA-4 treatment as monotherapy, and in combination with a PD-1 blocking agent. The event will feature Omid Hamid,...

Continue reading

Amethyst Beverage Closes Distribution Deal and Receives Order and Payment From Sovereign Development Group for Multiple Pallets of CBD Water

RANCHO CORDOVA, CA, Dec. 13, 2023 (GLOBE NEWSWIRE) — via NewMediaWire — Alternative Wellness Health, Inc. (EXMT), is pleased to announce the successful agreement with Tonto Tribal Development. We have closed an agreement for monthly purchases of all of our flavors of CBD 15 mg Premium Water. Tonto Tribal Development has agreed to utilize their “C” Store connections throughout the Native American Districts and distribute and sell our Orange Mango and Pineapple Coconut CBD 15 mg Premium Beverages. This first shipment has been paid for and will commence the monthly orders accordingly. This relationship creates a niche within the Native American markets that will initially include the “C” Stores and are expecting to build that into their Gaming industry as well. “We are very pleased to begin this transaction and are thrilled...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.